Shield To File ST10 Oral Iron-Deficiency Drug After Strong Phase III Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Shield Therapeutics will use robust Phase III data for its oral iron-deficiency therapy ST10 to seek marketing approval in Europe in the second half of 2014 for iron-deficiency anemia in inflammatory bowel disease, and then a subsequent NDA submission in the U.S. for treating iron-deficiency anemia in pre-dialysis patients with chronic kidney disease.
You may also be interested in...
Switzerland's Shield Therapeutics Raises $12M To Conduct Phase III Trials On Oral Iron Deficiency Product
Oral iron deficiency therapy to advance into Phase III this year on the back of $12 million fund raising for Swiss minnow, Shield Therapeutics.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.